4SC: overall survival benefit for resminostat in first-line liver cancer study subgroup

5. October 2016

|In Portfolio News

|By eazee-designstudio

Data from a randomized, multi-center, 170 patient Phase II study with resminostat as first-line treatment of advanced liver cancer presented at 2017 Gastrointestinal Cancers Symposium shows substantial increase in overall survival